We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

236 hedge funds and large institutions have $5.28B invested in Blueprint Medicines in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 82 increasing their positions, 81 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $31M | Put options by funds: $21.6M

20% more capital invested

Capital invested by funds: $4.39B → $5.28B (+$889M)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

7% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 27

1% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 81

1% more funds holding

Funds holding: 234 → 236 (+2)

0.19% less ownership

Funds ownership: 103.81% → 103.62% (-0.19%)

Holders
236
Holders Change
+2
Holders Change %
+0.85%
% of All Funds
4.76%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
29
Increased
82
Reduced
81
Closed
27
Calls
$31M
Puts
$21.6M
Net Calls
+$9.4M
Net Calls Change
+$21.3M

Top Buyers

Rank Fund Capital Flow
1
CCM
Cadian Capital Management
New York
+$115M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$75.2M
3
Macquarie Group
Macquarie Group
Australia
+$43.4M
4
TCM
TimesSquare Capital Management
New York
+$25.5M
5
N
Natixis
France
+$25.4M

Top Sellers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
-$58M
2
AG
Artal Group
Luxembourg
-$42.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$29M
4
Citadel Advisors
Citadel Advisors
Florida
-$27.3M
5
CS
Candriam SCA
Luxembourg
-$26.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCA
226
Berman Capital Advisors
Georgia
$3K – – –
ED
227
Exane Derivatives
France
$2.5K – – –
BAM
228
Bellevue Asset Management
Washington
$2K – – –
PA
229
Parallel Advisors
California
$2K – – –
IFAM
230
Institutional & Family Asset Management
Colorado
$2K +$539 +7 +39%
CWC
231
Carolinas Wealth Consulting
North Carolina
$2K +$1.54K +20 New
GWS
232
Glassman Wealth Services
Virginia
$1K – – –
TFO
233
Tarbox Family Office
California
$1K – – –
TPCW
234
TD Private Client Wealth
New York
$556 – – –
HM
235
HealthCor Management
New York
– -$58M -743,018 Closed
AG
236
Artal Group
Luxembourg
– -$42.9M -550,000 Closed
Alyeska Investment Group
237
Alyeska Investment Group
Illinois
– -$23.2M -296,858 Closed
FCMI
238
Foresite Capital Management III
California
– -$19.5M -249,598 Closed
IC
239
Ikarian Capital
Texas
– -$15.7M -201,662 Closed
SI
240
Sofinnova Investments
California
– -$7.4M -94,891 Closed
Hudson Bay Capital Management
241
Hudson Bay Capital Management
Connecticut
– -$4.68M -60,000 Closed
BFM
242
Boothbay Fund Management
New York
– -$1.89M -24,283 Closed
ESCM
243
Echo Street Capital Management
New York
– -$989K -12,678 Closed
Verition Fund Management
244
Verition Fund Management
Connecticut
– -$984K -12,620 Closed
MWNA
245
Marshall Wace North America
New York
– -$896K -11,481 Closed
JG
246
Jefferies Group
New York
– -$870K -11,299 Closed
AG
247
Algert Global
California
– -$843K -10,813 Closed
Allianz Asset Management
248
Allianz Asset Management
Germany
– -$689K -8,833 Closed
Thrivent Financial for Lutherans
249
Thrivent Financial for Lutherans
Minnesota
– -$460K -5,903 Closed
TRSOTSOK
250
Teachers Retirement System of the State of Kentucky
Kentucky
– -$456K -5,851 Closed
7 8 9
10
11

BPMC Hedge Fund Activity: Q3 2020 in Review

236 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2020, worth a combined $5.28B — up 20% from $4.39B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new BPMC positions and 27 closed out — a net gain of 2 holders — while 82 added to existing stakes and 81 trimmed.

The largest buyer was Cadian Capital Management, adding an estimated $115M. The largest seller was HealthCor Management, exiting entirely with an estimated $58M sold.

  • 236 institutional investors held Blueprint Medicines (BPMC) as of Q3 2020, up from 234 in Q2 2020.
  • Funds reported $5.28B of Blueprint Medicines stock for Q3 2020, up 20% quarter-over-quarter.
  • 29 funds opened new Blueprint Medicines positions in Q3 2020 and 27 closed out, a net change of +2 holders.
  • The largest Blueprint Medicines buyer in Q3 2020 was Cadian Capital Management, an estimated $115M added.
  • The largest Blueprint Medicines seller in Q3 2020 was HealthCor Management, an estimated $58M sold.

Based on aggregated 13F filings for Q3 2020.